A
Arthur P. Bertolino
Researcher at Novartis
Publications - 7
Citations - 2329
Arthur P. Bertolino is an academic researcher from Novartis. The author has contributed to research in topics: Secukinumab & Placebo-controlled study. The author has an hindex of 6, co-authored 7 publications receiving 2083 citations.
Papers
More filters
Journal ArticleDOI
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber,Bruce E. Sands,Steve Lewitzky,Marc Vandemeulebroecke,Walter Reinisch,Peter D.R. Higgins,Jan Wehkamp,Brian G. Feagan,Michael D Yao,Marek Karczewski,Jacek Karczewski,Nicole Pezous,Stephan Bek,Gerard Bruin,Bjoern Mellgard,Claudia Berger,Marco Londei,Arthur P. Bertolino,Gervais Tougas,Simon Travis +19 more
TL;DR: Blockade of IL-17A was ineffective and higher rates of adverse events were noted compared with placebo, and unfavourable responses on secukinumab were driven by patients with elevated inflammatory markers.
Journal ArticleDOI
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten,Xenofon Baraliakos,Jürgen Braun,Joachim Sieper,Paul Emery,Désirée van der Heijde,Iain B. McInnes,Jacob M van Laar,Robert Landewé,Paul Wordsworth,Paul Wordsworth,Jürgen Wollenhaupt,Herbert Kellner,Jacqueline E Paramarta,Jiawei Wei,Arndt Brachat,Stephan Bek,Didier Laurent,Yali Li,Ying A Wang,Arthur P. Bertolino,Sandro Gsteiger,Andrew M Wright,Wolfgang Hueber +23 more
TL;DR: Secukinumab rapidly reduced clinical or biological signs of active ankylosing spondylitis and was well tolerated, making it the first targeted therapy that is an alternative to tumour necrosis factor inhibition to reach its primary endpoint in a phase 2 trial.
Journal ArticleDOI
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes,Joachim Sieper,Juergen Braun,Paul Emery,Désirée van der Heijde,John D. Isaacs,Georg Dahmen,Jürgen Wollenhaupt,Hendrik Schulze-Koops,Joseph Kogan,Shenglin Ma,Martin Schumacher,Arthur P. Bertolino,Wolfgang Hueber,Paul P. Tak,Paul P. Tak +15 more
TL;DR: Although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit.
Journal ArticleDOI
Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor
Hans Skvara,Frank Kalthoff,Josef G. Meingassner,Barbara Wolff-Winiski,Heinrich Aschauer,Joseph Kelleher,Xu Wu,Shifeng Pan,Lesanka Mickel,Christopher Schuster,Georg Stary,Ahmad Jalili,Olivier J. David,Corinne Emotte,Ana Antunes,Kristine Rose,Jeremy Decker,Ilene Carlson,Humphrey Gardner,Anton Stuetz,Arthur P. Bertolino,Georg Stingl,Menno A. De Rie +22 more
TL;DR: Treatment with 0.75% LDE225 cream in NBCCS patients was very well tolerated and caused BCC regression, thus potentially offering an attractive therapeutic alternative to currently available therapies for this indication.
Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
I.B. McInnes,J. Sieper,J. Braun,Paul Emery,van der Heijde, , D.,J. Isaacs,G. Dahmen,Jürgen Wollenhaupt,Hendrik Schulze-Koops,Sandro Gsteiger,Arthur P. Bertolino,W. Hueber,P.P. Tak +12 more